DB:3G0

Stock Analysis Report

Executive Summary

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Altimmune's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3G0's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.0%

3G0

-4.9%

DE Biotechs

-3.0%

DE Market


1 Year Return

3.0%

3G0

-12.7%

DE Biotechs

-20.6%

DE Market

Return vs Industry: 3G0 exceeded the German Biotechs industry which returned -11.2% over the past year.

Return vs Market: 3G0 exceeded the German Market which returned -17.2% over the past year.


Shareholder returns

3G0IndustryMarket
7 Day8.0%-4.9%-3.0%
30 Day-10.3%-10.3%-19.1%
90 Day62.0%-22.8%-26.2%
1 Year3.0%3.0%-12.5%-12.7%-18.3%-20.6%
3 Yearn/a15.6%14.3%-18.8%-25.6%
5 Yearn/a-8.6%-11.0%-19.9%-30.7%

Price Volatility Vs. Market

How volatile is Altimmune's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Altimmune undervalued compared to its fair value and its price relative to the market?

1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3G0's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3G0's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3G0 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 3G0 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3G0's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3G0 is good value based on its PB Ratio (1.1x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-27.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3G0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 3G0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 3G0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 3G0's revenue is expected to decline over the next 3 years (-76.9% per year).

High Growth Revenue: 3G0's revenue is forecast to decline over the next 3 years (-76.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 3G0's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Altimmune performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3G0 is currently unprofitable.

Growing Profit Margin: 3G0 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3G0 is unprofitable, and losses have increased over the past 5 years at a rate of -28.6% per year.

Accelerating Growth: Unable to compare 3G0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3G0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 3G0 has a negative Return on Equity (-45.08%), as it is currently unprofitable.


Next Steps

Financial Health

How is Altimmune's financial position?


Financial Position Analysis

Short Term Liabilities: 3G0's short term assets ($39.4M) exceed its short term liabilities ($3.9M).

Long Term Liabilities: 3G0's short term assets ($39.4M) exceed its long term liabilities ($4.6M).


Debt to Equity History and Analysis

Debt Level: 3G0 is debt free.

Reducing Debt: 3G0 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 3G0 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 3G0's debt is not covered by short term assets (assets are -1.7741817691676E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3G0 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 3G0 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -16.7% each year


Next Steps

Dividend

What is Altimmune's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3G0's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 3G0's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3G0's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3G0's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3G0's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Vipin Garg (61yo)

1.42s

Tenure

US$2,189,964

Compensation

Dr. Vipin K. Garg, Ph.D. has been President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg served as Advisor of Neos Therapeutics, Inc. since June 27, 2018 until ...


CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD2.19M) is above average for companies of similar size in the German market ($USD428.68K).

Compensation vs Earnings: Insufficient data to compare Vipin's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Mitchel Sayare
Executive Chairman2.25yrsUS$189.62k0.0072% $3.0k
Vipin Garg
President1.42yrsUS$2.19m2.14% $895.3k
William Brown
CFO & Principal Accounting Officer1.92yrsUS$216.00k0.053% $22.3k
Bertrand Georges
Chief Technology Officer2.92yrsno datano data
M. Roberts
Chief Scientific Officer7.33yrsUS$290.39k0.037% $15.3k
José Ochoa
Chief Business Officer1.75yrsno datano data
Matthew Harris
Chief Medical Officer0.75yrno datano data

1.8yrs

Average Tenure

61yo

Average Age

Experienced Management: 3G0's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mitchel Sayare
Executive Chairman2.25yrsUS$189.62k0.0072% $3.0k
Vipin Garg
President1.42yrsUS$2.19m2.14% $895.3k
John Gill
Director15.67yrsUS$42.50k0.018% $7.7k
David Drutz
Independent Director2.92yrsUS$54.50k0.0046% $1.9k
Philip Hodges
Independent Director2.92yrsUS$59.94k0.13% $53.7k
John Petricciani
Member of Scientific Advisory Boardno datano datano data
Richard Whitley
Member of Scientific Advisory Boardno datano datano data
Klaus Schafer
Independent Director7.75yrsUS$47.67k0.0013% $551.4
Wayne Pisano
Independent Director1.67yrsUS$18.33k0.013% $5.5k

2.9yrs

Average Tenure

69yo

Average Age

Experienced Board: 3G0's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 368.4%.


Top Shareholders

Company Information

Altimmune, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Altimmune, Inc.
  • Ticker: 3G0
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$45.681m
  • Listing Market Cap: US$41.775m
  • Shares outstanding: 15.13m
  • Website: https://altimmune.com

Number of Employees


Location

  • Altimmune, Inc.
  • 910 Clopper Road
  • Suite 201S
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMay 2017
3G0DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2017

Biography

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 03:21
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.